Fuji Pharma cancels share options to prevent dilution

Fuji Pharma Co will acquire and cancel all remaining 1st Series Stock Acquisition Rights on August 1 for 6.5m yen. The move aims to prevent future dilution of 9.8% and avoid issuing shares below book value.

The company originally issued three series of stock acquisition rights totaling 49,000 units in August 2024 to fund growth initiatives in women's healthcare and biosimilars. It will assess future capital needs for the remaining 2nd and 3rd series.